Skylands Capital LLC Boosts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Skylands Capital LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 87.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,986 shares of the medical equipment provider’s stock after buying an additional 3,261 shares during the quarter. Skylands Capital LLC’s holdings in Zimmer Biomet were worth $738,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ZBH. Roman Butler Fullerton & Co. purchased a new stake in Zimmer Biomet during the fourth quarter valued at approximately $473,000. Geode Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after purchasing an additional 125,852 shares during the last quarter. M&T Bank Corp grew its stake in Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after buying an additional 8,709 shares during the last quarter. KLCM Advisors Inc. purchased a new stake in Zimmer Biomet in the fourth quarter valued at about $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $654,000. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the topic of several research reports. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities restated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Royal Bank of Canada dropped their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 1.2 %

Shares of NYSE:ZBH opened at $104.89 on Monday. The firm has a 50 day simple moving average of $105.86 and a 200-day simple moving average of $107.46. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $20.88 billion, a PE ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.